02:11 PM EST, 02/02/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Monday that topline results from a phase 3 trial show CagriSema led to a greater Hemoglobin A1c reduction and weight loss at week 68 compared with semaglutide across all tested doses.

The study, REIMAGINE 2, evaluated the efficacy and safety of CagriSema, which is a combination of cagrilintide and semaglutide, the company said.

The trial included adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor, the company said.

Data show that CagriSema achieved "superior" weight loss of up to 14.2%, according to the company.

The treatment also lowered HbA1c by up to 1.91 percentage points from a baseline of 8.2%, the company said, adding that the trial also confirmed that CagriSema was safe and well-tolerated.

Following the results of REIMAGINE 1 and REDEFINE 3, Novo Nordisk ( NVO ) plans to discuss the regulatory pathway for CagriSema in type 2 diabetes with health authorities, the company said.

Price: 59.08, Change: -0.35, Percent Change: -0.59